Keyword: Massachusetts Institute of Technology
Pardis Sabeti, co-founder, Sherlock Biosciences
Alexandra “Sandra” Glucksmann, CEO, Cedilla Therapeutics
Biosims haven't worked, experts say. Instead, it's time to for an independent body to set fair biologic prices after the drugs lose exclusivity.
Here’s a radical solution for hepatitis C treatment in the U.S.: The government could buy Gilead Sciences. Price: $156 billion. Payoff: Curing hep C patients at one-third the cost.